Scopus BioPharma Inc. SCPS
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 45.31% | 66.68% | 56.93% | 23.68% | -- |
| Total Depreciation and Amortization | -50.00% | -27.78% | 6.25% | 18.75% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -291.86% | -- |
| Total Other Non-Cash Items | -42.02% | -100.00% | -98.06% | -90.61% | -- |
| Change in Net Operating Assets | 91.08% | 37.53% | 13.85% | 636.03% | -- |
| Cash from Operations | 77.49% | 61.06% | 28.87% | -44.64% | -- |
| Capital Expenditure | 100.00% | 100.00% | 20.00% | 20.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | 100.00% | 20.00% | 20.00% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | -- |
| Issuance of Common Stock | -90.42% | -90.77% | -- | -23.73% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 200.97% | 205.66% | 109.92% | 35.55% | -- |
| Cash from Financing | -73.54% | -72.94% | -98.62% | -25.86% | -- |
| Foreign Exchange rate Adjustments | -24.46% | 358.54% | 451.30% | 284.78% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 84.44% | 39.89% | -227.94% | -203.42% | -- |